For the Inventor, By the Inventor

Enter assignee name

Chicago, IL, United States of America

Xeris Pharmaceuticals, Inc.

USPTO Granted Patents = 29

% Expired Patents = 3.4

CIPO Patents = 2

EPO Patents = 10

Trademarks = 5

Forward Citations = 160

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Steven J Prestrelski (25 out of 28 patents)

Martin J Donovan (9 out of 27 patents)

John Kinzell (6 out of 6 patents)

4. Michael A Sandoval (5 out of 6 patents)

5. Wendy Hu (5 out of 5 patents)

6. Nancy Scott (3 out of 3 patents)

7. Kevin J Brodbeck (3 out of 7 patents)

8. Richard Fitch (3 out of 3 patents)

9. Brian R Sloat (2 out of 4 patents)

10. Fredric Cohen (1 out of 12 patents)

11. Wei-Jie Fang (1 out of 1 patent)

12. John Frank Carpenter (1 out of 31 patents)

13. Brett Newswanger (1 out of 1 patent)

14. Evan Cassavaugh (1 out of 1 patent)

15. Martin Cummins (1 out of 1 patent)

Core Competencies:

Levothyroxine

Glucagon

Hypoglycemia

Aprotic Solvents

Sustained Release

Parenteral Injection

Small Molecule Drugs

Peptide Drugs

Drug Formulations

Therapeutic Compositions

Intracutaneous Injection

Exercise-Induced Hypoglycemia

29 patents: Sort by Forward Citations

1. 12751937 - Stable levothyroxine compositions in aprotic polar solvents (2026-10-06),

2. 12691089 - Stable levothyroxine compositions in aprotic polar solvents (2026-07-28),

3. 12514907 - Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes (2026-01-06),

4. 12514837 - Stable levothyroxine compositions in aprotic polar solvents (2026-01-06),

5. 12377096 - Methods of treating disease with levoketoconazole (2025-08-05),

6. 11964003 - Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same (2024-04-23),

7. 11957736 - Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same (2024-04-16),

8. 11833157 - Precipitation resistant small molecule drug formulations (2023-12-05),

9. 11590205 - Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents (2023-02-28),

10. 11576951 - Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same (2023-02-14),

11. 11446310 - Stable formulations for parenteral injection of small molecule drugs (2022-09-20),

12. 11129940 - Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes (2021-09-28),

13. 11020403 - Precipitation resistant small molecule drug formulations (2021-06-01),

14. 10987399 - Stable formulations for parenteral injection of peptide drugs (2021-04-27),

15. 10765683 - Stable formulations for parenteral injection of small molecule drugs (2020-09-08),

Company Overview

Xeris Pharmaceuticals, Inc. is a biopharmaceutical company based in Chicago, Illinois, focused on developing and commercializing innovative therapies for patients with chronic diseases. The company specializes in formulation technologies that enhance the delivery of injectable medications, aiming to improve patient outcomes and adherence. Xeris leverages its proprietary technology platforms to create products that address unmet medical needs, particularly in the areas of diabetes and other chronic conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

29 Patents

#152 in Chicago, IL

#623 in Illinois

#11,625 in US

#22,552 in the World

Chicago, IL, United States of America

Xeris Pharmaceuticals, Inc.

Forward Citations = 160

16 inventors:

Steven J Prestrelski (25 out of 28 patents)

Martin J Donovan (9 out of 27 patents)

John Kinzell (6 out of 6 patents)

4. Michael A Sandoval (5 out of 6 patents)

5. Wendy Hu (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xeris Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/xeris-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…